View Older Stories View More Recent Stories
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
European drug panel recommends Regeneron's Libtayo for skin cancer use
-
Regeneron presents new cancer treatment data at ESMO meeting
-
Canaccord Genuity Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility
-
Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
FDA approves Regeneron's Libtayo for skin cancer prevention
-
FDA approves Regeneron's Libtayo for high-risk skin cancer treatment
-
Regeneron Pharma (REGN) PT Raised to $704 at RBC Capital
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
FDA approves Regeneron's Evkeeza for children as young as 1 with rare cholesterol disorder
-
Regeneron and Sanofi receive positive EU opinion for Dupixent CSU treatment
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Regeneron reports five-year survival data for Libtayo lung cancer treatment
-
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
-
Regeneron (REGN) See Strength Following Opening Bell Weakness, Now up Over 2pct
-
Regeneron (REGN) Shares Decline on the Open
-
Raymond James Comments on REGN and AMGN Earlier
-
Raymond James Assumes Regeneron Pharma (REGN) at Outperform
-
Why public perception matters so much for biotech valuations
-
UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)
-
Regeneron Pharma (REGN) PT Raised to $781 at Bernstein
-
Regeneron Pharma (REGN) PT Raised to $831 at Jefferies
-
TD Cowen on Regeneron Pharma (REGN): 'More Going On Under the Hood Than Appreciated'
-
Rothschild Redburn Starts Regeneron Pharma (REGN) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Regeneron Pharma (REGN) PT Lowered to $812 at Truist Securities
-
Regeneron Pharma (REGN) PT Raised to $695 at RBC Capital
-
Regeneron Pharma (REGN) PT Raised to $640 at BMO Capital
-
Leerink: 'We continue to recommend REGN shares'
-
Regeneron Pharma (REGN) PT Raised to $753 at Bernstein SocGen Group
-
Regeneron Pharma (REGN) PT Raised to $815 at Guggenheim
-
Regeneron (REGN) Tops Q2 EPS by 439c
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Regeneron Pharma (REGN) PT Raised to $584 at UBS
-
Bernstein Reiterates Outperform Rating on Regeneron Pharma (REGN)
-
JPMorgan Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron (REGN) Reports Lynozyfic Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
-
These 30 global stocks offer tactical and structural upside, says RBC
-
Regeneron the purchaser of Abeona Therapeutics (ABEO) FDA priority review voucher
-
Regeneron (REGN) Announces Dupixent Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid
-
23andMe (MEHCQ) Reaches Agreement for Sale of Business to TTAM Research Institute
-
Regeneron (REGN) Executive: 23andMe Auction Process Was Recently Reopened and is "Fairly Complicated" - Goldman Sachs Conference
-
Regeneron Pharma (REGN) PT Lowered to $800 at JPMorgan
-
Regeneron Pharma (REGN) PT Lowered to $560 at UBS
